<DOC>
	<DOCNO>NCT02411331</DOCNO>
	<brief_summary>Implantable venous access port infection mainly due coagulase negative staphylococci may manage antibiotic lock therapy retention port . Most time vancomycin lock use . Experimental data show vancomycin may poorly effective eradicate staphylococcal biofilm port . Another disadvantage Vancomycin-containing lock solution occurrence resistant organism risk catheter occlusion . Ethanol-containing lock solution highly effective vitro expose risk emergence resistance .</brief_summary>
	<brief_title>Randomized , Multicenter , Double-blind , Vancomycin-controlled Study Evaluate Efficacy Ethanol Lock Solution Curative Treatment Implantable Venous Access Port Infection Due Coagulase-negative Staphylococci</brief_title>
	<detailed_description>Type study : multi-center , randomize , double-blind , parallel-group , control clinical trial . Number center : 9 French center Auvergne Rhône-Alpes region Medical product Ethanol 40 % + Enoxaparine 400UI/ml Versus Vancomycin 5 mg/ml + Héparine 2500UI/ml Patients Patients eligible inclusion randomize one two group : - Experimental group : 90 patient receive 10 injection ethanol lock solution implantable venous access port first 10 day study . - Control group : 90 patient receive 10 injection vancomycin lock solution implantable venous access port first 10 day study . - For group , case bacteraemia , lock therapy associate systemic antibiotic therapy use another venous line optimize specialist infectious disease . Study Performance Patients assess baseline D0 , 3 day ( D3 ) , 10 day ( D10 ) , 14 week ( W14 ) D0 follow : Visit 1 ( D0 - baseline ) : - Signature informed consent form . - Demographic clinical characteristic ( sex , age , disease associate implantable venous access port , implantable venous access port infection data , bacteraemia data ) Days 1 10 - Injection ethanol vancomycin lock solution implantable venous access port - Ethanolemia 30 minute injection , first day - Side effect evaluation Visit 2 ( D3 ) Visit 3 ( D10 ) - Side effect evaluation - Blood culture - Bacteraemia data ( antibiotic therapy modification ) Phone contact week week 2 week 13 End Visit ( W14 ) - Side effect evaluation - Blood culture - Bacteraemia data ( antibiotic therapy modification )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Coagulase</mesh_term>
	<criteria>Man woman 18 year old With probable definite implantable venous access port infection With without bacteraemia Infection due coagulasenegative staphylococci ( except lugdunensis Staphylococci ) Blood culture result available within 48 hour inclusion With health insurance Pregnant breastfeed woman Allergy ethanol Patient prosthetic cardiac valve Necessity venous access port withdrawal Prior infection venous access port Patients supervision ( legal ) guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lock Solution</keyword>
	<keyword>Catheter relate blood stream infection</keyword>
	<keyword>Central venous catheter infection</keyword>
	<keyword>Intravenous Drug Delivery Systems</keyword>
	<keyword>Coagulase-negative staphylococci infection</keyword>
	<keyword>Ethanol lock solution</keyword>
	<keyword>Vancomycin lock solution</keyword>
</DOC>